Losartan Tablet

Losartan Potassium Tablets USP / BP / IP (250 mg / 50 mg / 100 mg)

First-Line Angiotensin II Receptor Blocker (ARB) Anti-Hypertensive

Healthy Life Pharma Private Limited, alongside our specialized global export and marketing division Healthy Inc, is a leading Indian manufacturer, CDMO services provider, and wholesale exporter of advanced cardiovascular, renal, and metabolic therapeutics. We manufacture a comprehensive, internationally standardized range of Losartan Potassium Tablets inside our state-of-the-art, WHO–GMP certified, high-capacity solid dosage manufacturing lines.

Serving as a foundational therapeutic baseline for chronic cardiovascular management, this product is a massive-volume strategic export to national health ministries, state hospital purchasing cooperatives, retail pharmacy distribution networks, and international digital B2B pharmaceutical marketplaces across Africa, the CIS region, LATAM, and South-East Asia.

Product Overview

This formulation operates as an “Angiotensin II Receptor Antagonist.” It ensures long-term cardiovascular stabilization and renal protection by selectively blocking the hormone paths that force blood vessels to constrict and retain excess fluid.

• Mechanism 1 (Selective AT1 Receptor Blockade): Losartan and its long-acting active carboxylic acid metabolite ($E\text{-}3174$) physically bind with high selectivity and affinity to the Angiotensin II Type 1 ($\text{AT}_{1}$) receptor located on vascular smooth muscle and adrenal gland cell membranes.

• Mechanism 2 (Vasoconstriction Inactivation): By physically blocking Angiotensin II from binding to the $\text{AT}_{1}$ receptor, it completely prevents the chemical cascade that induces smooth muscle contraction. This forces peripheral blood vessels to dilate (vasodilation), immediately reducing total peripheral vascular resistance to lower arterial blood pressure.

• Mechanism 3 (Aldosterone Secretion Inhibition & Nephroprotection): The blockade chemically halts Angiotensin II-stimulated aldosterone secretion from the adrenal cortex. This reduces renal sodium and water retention, safely lowering circulating blood volume while lowering intraglomerular pressure, which slows down the progression of diabetic kidney damage (nephroprotection).

Product Composition & Available Strengths

We supply Losartan Potassium across the complete, internationally recognized therapeutic range to facilitate progressive dose titrations and precise maintenance regimens.

Technical & Logistics Specifications

• HS Code: 3004.90.79 (Medicaments acting on the cardiovascular system / Anti-hypertensives / Angiotensin Receptor Blockers) or 3004.90.99 (General Category)

• CAS Number: 124750-99-8 (Losartan Potassium) / 114798-26-4 (Losartan Base)

• Dosage Form: Oral Solid Film-Coated Tablet (Core matrix precisely film-coated to shield the active compound from light and ambient oxidation)

• Packaging Configurations: 10 or 14 Tablets per Blister Strip packed in high-barrier Alu-Alu (Cold-Form Foil) or thick moisture-shield PVC/PVDC matrix strips. Losartan Potassium is highly hygroscopic; our premium tropicalized packaging completely isolates the active core, guaranteeing a full 36-month shelf life in hot, humid Zone IVb export environments.

Advanced Manufacturing Integrity & Quality Controls

• Moisture-Controlled Granulation Suites: Losartan Potassium raw material absorbs moisture rapidly when exposed to air, which can compromise tablet hardness and degradation profiles. We operate our complete blending, wet granulation, and drying lines inside Advanced Climate-Controlled Processing Blocks with relative humidity strictly maintained below 35%, preserving crystalline integrity.

• High-Velocity Compression Uniformity: To guarantee absolute weight uniformity across continuous high-output million-unit production runs, our tablet presses utilize Automated Forced-Feeder Die Matrix Modules and Online Electronic Hardness Verifiers, ensuring flawless content uniformity.

• Bioequivalence and Dissolution Kinetics: Every single production batch physically undergoes strict Automated In-Vitro Dissolution Profiling, chemically validating that our generic tablets precisely match the rapid disintegration and plasma-absorption curves of global innovator references (such as Cozaar).

Primary Indications

• Cardiology: First-line treatment of Chronic Essential Hypertension in adults and pediatric patients aged greater than 6 years.

• Stroke Prophylaxis: Reduction of the risk of sudden stroke in hypertensive patients presenting with documented Left Ventricular Hypertrophy (LVH).

• Nephrology: Long-term treatment of Diabetic Nephropathy in patients presenting with Type 2 Diabetes Mellitus and elevated serum creatinine, significantly slowing down chronic renal disease progression.

Usage Instructions

• Administration Matrix: Take the tablet orally once daily with a full glass of water. It can be administered consistently either with or without food.

• The Initial Dizziness Window: Losartan may induce transient orthostatic hypotension (dizziness upon standing) during initial therapy startup or following step-up strength modifications. Advise patients to move physically slow when changing positions during the first week.

• The Serum Potassium Rule: Because blocking aldosterone can chemically lead to potassium retention, patients must avoid excessive use of potassium supplements or potassium-containing salt substitutes without regular medical monitoring of serum potassium levels.

Safety Warning: POTENT FIRST-LINE CARDIOVASCULAR ANTI-HYPERTENSIVE. For Physician / Cardiologist Supervision Only. The Fetal Toxicity Mandate: ABSOLUTELY CONTRAINDICATED IN PREGNANCY. Drugs that act directly on the renin-angiotensin system chemically induce severe fetal injury, renal failure, and neonatal death if administered during the second and third trimesters; discontinue immediately if pregnancy is detected. Renal Function Note: Monitor renal parameters ($BUN$/Creatinine) closely in patients presenting with bilateral renal artery stenosis to prevent severe acute renal drop. Contraindications: Absolute contraindications in pregnant patients, co-administration with Aliskiren in patients presenting with diabetes, or known hypersensitivity to angiotensin receptor blocker matrices.

Global CDMO Services & Wholesale Supply Chain

Healthy Life Pharma Private Limited and Healthy Inc provide complete, internationally validated Third-Party Contract Manufacturing (CDMO Services) and bulk private-label export pipelines for the entire Losartan Potassium portfolio. Because this molecule faces zero controlled-substance dual-licensing regulatory hurdles, our high-capacity lines can rapidly manufacture, release, and ship multi-container shipping loads. We deliver all required documentation (WHO-GMP Certificate, Certificates of Pharmaceutical Product – COPP, Certificates of Analysis – COA, Stability Matrix Sheets, and Complete CTD Format Dossier sets) for rapid entry registration.

Commercial & Bulk Procurement Inquiries:

• Corporate Head Office: Mumbai, Maharashtra, India

• Primary Manufacturing Base: Boisar, Maharashtra, India

• WhatsApp / Direct Call: +91 7710003340

• Corporate Email: info@healthyinc.co.in